Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
NEVRO CORP
Jurisdiction of Incorporation/Organization
DE
Year of Incorporation/Organization
2006
Item 2 Issuer Principal Place of Business and Contact Information
4040 CAMPBELL AVENUE
SUITE 210
MENLO PARK, CA 94025
Phone Number:
subscription required
Item 3. Related Persons
Name
MICHAEL DEMANE
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
KONSTANTINOS ALATARIS
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
JOHN DEEDRICK
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
BILL HARRINGTON
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
VINCE KIM
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
MARK KNUDSON
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
BILL MOFFITT
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
NATHAN PLIAM
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
JON TREMMEL
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
ANDREW GALLIGAN
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
BIOTECHNOLOGY
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
DECLINE TO DISCLOSE
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
07/15/2011
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
- Equity
- Other: SERIES B PREFERRED STOCK; COMMON STOCK ISSUABLE UPON CONVERSION THEREOF
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
58604692
Total Amount Sold
58604692
Total Remaining to be Sold
0
Clarification of Response
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
13
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
Signature and Submission
Issuer Name
NEVRO CORP
Issuer Signature
/S/ MICHAEL DEMANE
Signer Name
MICHAEL DEMANE
Signer Title
CHIEF EXECUTIVE OFFICER
Signature Date
07/26/2011